Overview
- Editors:
-
-
John R. J. Sorenson
-
Department of Biopharmaceutical Sciences, College of Pharmacy and Department of Pharmacology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA
Access this book
Other ways to access
Table of contents (58 chapters)
-
-
Physiological Aspects of Copper Metabolism
-
-
- Gary W. Evans, W. Thomas Johnson
Pages 3-15
-
-
-
- David R. Williams, C. Furnival, Peter M. May
Pages 45-59
-
- M. J. Laroche, P. Chappuis, Y. Henry, F. Rousselet
Pages 61-72
-
Physiological Aspects of Copper Metabolism
-
-
-
- J. Camakaris, D. M. Danks, M. Phillips, S. Herd, J. R. Mann
Pages 85-96
-
-
- Carl L. Keen, Bo Lönnerdal, Lucille S. Hurley
Pages 109-121
-
-
-
Biochemical Aspects of Copper Metabolism
-
-
- Robert J. Cousins, Alan L. Weiner
Pages 147-157
-
-
- A. Zgirski, M. V. Chidambaram, E. Frieden
Pages 171-181
-
- Edward D. Harris, Robert A. DiSilvestro, James E. Balthrop
Pages 183-198
-
About this book
In 1928, it was discovered that copper was essential for normal human metabolism. A decade later, in 1938, it was observed that patients with rheu matoid arthritis exhibited a higher than normal serum copper concentration that returned to normal with remission of this disease. Thirteen years later, it was found that copper complexes were effective in treating arthritic dis eases. The first report that copper complexes had antiinflammatory activity in an animal model of inflammation appeared twenty-two years after the dis covery of essentiality. In 1976, it was suggested that the active forms of the antiarthritic drugs are their copper complexes formed in vivo. This sugges tion has been confirmed and extended in the interim in over 200 recent publications. Individual biomedical scientists from many countries who have published in these areas recently saw a need for a meeting to exchange current re supporting new hypotheses. We search results and discuss the evidence met on the University of Arkansas Medical Sciences campus in Little Rock, Arkansas, August 10-13, 1981. Participants came from Australia, England, France, Germany, Israel, Italy, The Netherlands, Norway, Poland, Scotland, Sweden, Switzerland, Wales, Zimbabwe, and over twenty of the United States.
Editors and Affiliations
-
Department of Biopharmaceutical Sciences, College of Pharmacy and Department of Pharmacology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, USA
John R. J. Sorenson
